MX345883B - Composiciones de peptidos en nanoparticulas. - Google Patents
Composiciones de peptidos en nanoparticulas.Info
- Publication number
- MX345883B MX345883B MX2014002418A MX2014002418A MX345883B MX 345883 B MX345883 B MX 345883B MX 2014002418 A MX2014002418 A MX 2014002418A MX 2014002418 A MX2014002418 A MX 2014002418A MX 345883 B MX345883 B MX 345883B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- linker
- nanoparticles
- amino acid
- core
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000002105 nanoparticle Substances 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 239000003446 ligand Substances 0.000 abstract 3
- 125000000837 carbohydrate group Chemical group 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000004065 semiconductor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Nanotechnology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161531745P | 2011-09-07 | 2011-09-07 | |
| PCT/EP2012/067561 WO2013034726A1 (en) | 2011-09-07 | 2012-09-07 | Nanoparticle-peptide compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014002418A MX2014002418A (es) | 2014-10-13 |
| MX345883B true MX345883B (es) | 2017-02-22 |
Family
ID=46829760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014002418A MX345883B (es) | 2011-09-07 | 2012-09-07 | Composiciones de peptidos en nanoparticulas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9598479B2 (enExample) |
| EP (1) | EP2753360B1 (enExample) |
| JP (1) | JP6077544B2 (enExample) |
| KR (1) | KR102001269B1 (enExample) |
| CN (1) | CN103917249B (enExample) |
| AU (1) | AU2012306243B2 (enExample) |
| BR (1) | BR112014005242B1 (enExample) |
| EA (1) | EA025758B1 (enExample) |
| ES (1) | ES2627507T3 (enExample) |
| IN (1) | IN2014MN00433A (enExample) |
| MX (1) | MX345883B (enExample) |
| WO (1) | WO2013034726A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| WO2013034741A1 (en) * | 2011-09-07 | 2013-03-14 | Midatech Limited | Nanoparticle tumour vaccines |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| PT3065771T (pt) | 2013-11-04 | 2019-06-24 | Uti Lp | Metodos e composicoes para imunoterapia prolongada |
| CN104606674B (zh) * | 2014-07-25 | 2018-02-09 | 武汉博沃生物科技有限公司 | 轮状病毒多糖‑蛋白结合疫苗及其制备方法 |
| CN107412764B (zh) * | 2014-07-25 | 2020-08-11 | 武汉博沃生物科技有限公司 | 一种肺炎球菌缀合疫苗及其制备方法 |
| CN107029225B (zh) * | 2014-07-25 | 2020-08-11 | 武汉博沃生物科技有限公司 | 一种缀合疫苗及其制备方法 |
| KR101694121B1 (ko) | 2014-10-28 | 2017-01-10 | (주)헵틸와이 | 이중 가교구조의 생체친화형 다공성 시트 및 그 제조방법 |
| KR20160067472A (ko) | 2014-12-04 | 2016-06-14 | (주)헵틸와이 | 생체친화형 섬유상 매트릭스, 이를 포함하는 마스크 팩 및 그 제조방법 |
| AU2016275312B2 (en) | 2015-05-06 | 2021-12-23 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
| GB2541166A (en) * | 2015-07-24 | 2017-02-15 | Midatech Ltd | Nanoparticle-based liver-targeting therapy and imaging |
| CN110290805A (zh) * | 2017-01-03 | 2019-09-27 | 埃默杰克斯疫苗控股有限公司 | 通用流感疫苗组合物 |
| KR102015805B1 (ko) * | 2017-05-11 | 2019-08-29 | 서울대학교산학협력단 | 유기 반도체 물질의 자기조립 나노구조체 및 제조방법 |
| SG11202002044WA (en) | 2017-09-21 | 2020-04-29 | Emergex Vaccines Holding Ltd | MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus |
| AU2018374569B2 (en) | 2017-11-29 | 2024-10-17 | Uti Limited Partnership | Methods of treating autoimmune disease |
| US11690904B2 (en) | 2018-01-06 | 2023-07-04 | Emergex Vaccines Holding Limited | MHC class I associated peptides for prevention and treatment of multiple flavi virus |
| EP3773705A1 (en) | 2018-03-29 | 2021-02-17 | Emergex Vaccines Holdings Limited | Vaccine compositions |
| WO2019186200A1 (en) | 2018-03-29 | 2019-10-03 | Emergex Vaccines Holding Limited | Vaccine compositions |
| MX2020012373A (es) | 2018-05-18 | 2021-02-09 | Emergex Vaccines Holding Ltd | Vacuna de peptido inverso. |
| RU2695135C1 (ru) * | 2018-07-11 | 2019-07-22 | Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства | Двухуровневая микрогранулированная форма терапевтического пептида для перорального применения и способ ее получения |
| CN112218877B (zh) | 2018-08-27 | 2025-07-25 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| GB201820471D0 (en) * | 2018-12-14 | 2019-01-30 | Midatech Ltd | Nanoparticle-based therapy of inflammatory disorders |
| GB201820470D0 (en) * | 2018-12-14 | 2019-01-30 | Midatech Ltd | Antifolate-carrying nanoparticles and their use in medicine |
| AU2021239080A1 (en) | 2020-03-15 | 2022-09-29 | Nanocarry Therapeutics Ltd. | Nano-delivery system and therapeutic and diagnostic use thereof |
| EP3909612A1 (en) | 2020-05-12 | 2021-11-17 | Life Science Inkubator Betriebs GmbH & Co. KG | Composition of nanoparticles |
| GB202008250D0 (en) | 2020-06-02 | 2020-07-15 | Emergex Vaccines Holding Ltd | Diagnosis, prevention and treatment of coronavirus infection |
| EP4294435A1 (en) | 2021-02-16 | 2023-12-27 | Emergex Vaccines Holding Limited | Reverse peptides from coronavirus for immunogenic purposes |
| CN113209046B (zh) * | 2021-05-08 | 2022-09-09 | 中国人民解放军陆军军医大学 | 一种CoSe@BSA纳米粒子药物组合物及其制备方法和应用 |
| WO2022253917A1 (en) | 2021-06-02 | 2022-12-08 | Emergex Vaccines Holding Limited | Human coronavirus 229e derived peptides |
| CA3225403A1 (en) * | 2021-07-14 | 2023-01-19 | Rachela Popovtzer | Brain permeable multifunctional system and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
| GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
| GB0313259D0 (en) | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
| IL158140A0 (en) * | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
| ES2242528B1 (es) | 2004-03-25 | 2006-12-01 | Consejo Sup. Investig. Cientificas | Nanoparticulas magneticas de metales nobles. |
| JP5398982B2 (ja) | 2004-05-24 | 2014-01-29 | ミダテック リミテッド | Ｒｎａリガンドを含むナノ粒子 |
| JP5117191B2 (ja) * | 2004-10-01 | 2013-01-09 | ミダテック リミテッド | 抗原及びアジュバントを含むナノ粒子、並びに免疫原性構造 |
| CN101123990A (zh) * | 2004-10-01 | 2008-02-13 | Mida科技有限公司 | 包含抗原和佐剂的纳米颗粒，和免疫原性结构 |
| WO2007015105A2 (en) * | 2005-08-04 | 2007-02-08 | Thomas William Rademacher | Nanoparticles comprising antibacterial ligands |
| AU2007242572B2 (en) | 2006-04-13 | 2011-11-24 | Midatech Limited | Nanoparticles containing three various ligands for providing immune responses against infectious agents |
| EP2161279A1 (en) * | 2008-08-29 | 2010-03-10 | Centre National de la Recherche Scientifique | Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies |
| US8343497B2 (en) * | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| US9764012B2 (en) | 2009-04-01 | 2017-09-19 | University Of Miami | Vaccine compositions and methods of use thereof |
| CA2772551A1 (en) | 2009-08-26 | 2011-03-03 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| EP2305310A1 (en) | 2009-09-25 | 2011-04-06 | Asociación Centro de Investigación Cooperativa en Biomateriales - CIC biomaGUNE | Gold -coated magnetic glyconanoparticles functionalised with proteins for use as diagnostic and therapeutic agents |
| TWI485245B (zh) | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗 |
| WO2013034741A1 (en) | 2011-09-07 | 2013-03-14 | Midatech Limited | Nanoparticle tumour vaccines |
-
2012
- 2012-09-07 IN IN433MUN2014 patent/IN2014MN00433A/en unknown
- 2012-09-07 MX MX2014002418A patent/MX345883B/es active IP Right Grant
- 2012-09-07 CN CN201280049979.0A patent/CN103917249B/zh active Active
- 2012-09-07 KR KR1020147009090A patent/KR102001269B1/ko active Active
- 2012-09-07 AU AU2012306243A patent/AU2012306243B2/en not_active Ceased
- 2012-09-07 ES ES12756725.3T patent/ES2627507T3/es active Active
- 2012-09-07 JP JP2014529001A patent/JP6077544B2/ja active Active
- 2012-09-07 WO PCT/EP2012/067561 patent/WO2013034726A1/en not_active Ceased
- 2012-09-07 BR BR112014005242-5A patent/BR112014005242B1/pt active IP Right Grant
- 2012-09-07 US US14/343,083 patent/US9598479B2/en active Active
- 2012-09-07 EA EA201490415A patent/EA025758B1/ru not_active IP Right Cessation
- 2012-09-07 EP EP12756725.3A patent/EP2753360B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2627507T3 (es) | 2017-07-28 |
| JP6077544B2 (ja) | 2017-02-08 |
| EP2753360A1 (en) | 2014-07-16 |
| EP2753360B1 (en) | 2017-04-26 |
| BR112014005242A2 (pt) | 2018-06-05 |
| MX2014002418A (es) | 2014-10-13 |
| US20140341938A1 (en) | 2014-11-20 |
| AU2012306243A1 (en) | 2014-03-13 |
| AU2012306243B2 (en) | 2016-10-20 |
| KR102001269B1 (ko) | 2019-07-17 |
| IN2014MN00433A (enExample) | 2015-06-19 |
| CN103917249A (zh) | 2014-07-09 |
| EA201490415A1 (ru) | 2014-08-29 |
| JP2014527960A (ja) | 2014-10-23 |
| EA025758B1 (ru) | 2017-01-30 |
| US9598479B2 (en) | 2017-03-21 |
| BR112014005242B1 (pt) | 2022-07-26 |
| CN103917249B (zh) | 2016-11-09 |
| WO2013034726A1 (en) | 2013-03-14 |
| KR20140069101A (ko) | 2014-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX345883B (es) | Composiciones de peptidos en nanoparticulas. | |
| Buschbeck et al. | Homoleptic transition metal acetylides | |
| WO2015006740A3 (en) | Oligonucleotide-ligand conjugates and process for their preparation | |
| PH12015502180A1 (en) | Wt1-antigen peptide conjugate vaccine | |
| MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
| MX340558B (es) | Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro. | |
| UA111470C2 (uk) | Спосіб отримання частинок зі зменшеними електростатичними зарядами | |
| IN2014CN04160A (enExample) | ||
| GB201103836D0 (en) | Conjugation process | |
| WO2011154711A8 (en) | Peptide-carrying nanoparticles | |
| TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
| MY196510A (en) | Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors | |
| MX2008016039A (es) | Preparacion de glucano. | |
| WO2013055684A8 (en) | Rasagiline citramide | |
| EP3513794A3 (en) | Fucose analogs for inhibition of protein fucosylation in vivo | |
| MY182178A (en) | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration | |
| PL400162A1 (pl) | Nowe kompleksy rutenu, ich zastosowanie w reakcjach metatezy oraz sposób prowadzenia reakcji metatezy | |
| TN2013000373A1 (en) | Pharmaceutical formulation comprising inositol | |
| EP3747891A3 (en) | Compositions and methods for conjugating oligonucleotides | |
| IN2014DN09367A (enExample) | ||
| MX2014002625A (es) | Nuevas composiciones para la produccion de poliamidas coladas. | |
| GB201303865D0 (en) | Pharmaceutical composition and method of inhibiting of production or amplifyingelimination of P24 protein | |
| UA113413C2 (uk) | Пептид mphosph1 та вакцина, що його містить | |
| EP2547666A4 (en) | 1,4,7-TRIAZA-CYCLONONAN CONJUGATES, DINUCLEAR METAL COMPLEXES OF SUCH CONJUGATES, AND METHODS OF USING 1,4,7-TRIAZA-CYCLONONANES AND CONJUGATES | |
| PH12015501033A1 (en) | Peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |